NCT01340053 - A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C) | Biotech Hunter

Enrollment

186

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

December 31, 2011

Study Completion Date

February 29, 2012

Conditions

Constipation Predominant Irritable Bowel Syndrome

Interventions

DRUG

RDX5791

Capsule, QD

Trial Locations (16)

11214

Ardelyx Investigational Site, Brooklyn

21401

Ardelyx Investigational Site, Annapolis

24502

Ardelyx Investigational Site, Lynchburg

27408

Ardelyx Investigational Site, Greensboro

29681

Ardelyx Investigational Site, Simpsonville

33458

Ardelyx Investigational Site, Jupiter

33782

Ardelyx Investigational Site, Pinellas Park

37620

Ardelyx Investigational Site, Bristol

48047

Ardelyx Investigational Site, Chesterfield

61107

Ardelyx Investigational Site, Rockford

63128

Ardelyx Investigational Site, St Louis

66202

Ardelyx Investigational Site, Mission

71201

Ardelyx Investigational Site, Monroe

73104

Ardelyx Investigational Site, Oklahoma City

84405

Ardelyx Investigational Site, Ogden

92108

Ardelyx Investigational Site, San Diego